Hori Hisako, Shimoyoshi Satomi, Tanaka Yasuhiro, Momonami Ayaka, Masumura Kenichi, Yamada Masami, Fujii Wataru, Kitagawa Yoshinori, Hayashi Makoto
Suntory MONOZUKURI Expert Limited, 8-1-1 Seikadai, Seika-cho, Soraku-gun, Kyoto 619-0284, Japan.
Suntory Wellness Limited, 8-1-1 Seikadai, Seika-cho, Soraku-gun, Kyoto 619-0284, Japan.
Mutat Res Genet Toxicol Environ Mutagen. 2020 Jan;849:503130. doi: 10.1016/j.mrgentox.2019.503130. Epub 2019 Dec 27.
Human risk assessment of the toxic potency of chemicals typically includes genotoxicity assays for predicting carcinogenicity. Gene mutation frequency and chromosomal aberration are two major genotoxicity endpoints in standardized in vitro and in vivo assays. The weight-of-evidence approach in risk assessment is more focused on in vivo assay results; however, animal welfare considerations are aimed at the reduction, replacement, and refinement (3R's) of animal experiments, including a reduction in the number of experimental animals. Proposals to reduce experimental animals in genotoxicity testing include the incorporation of genotoxicity endpoint(s) into other toxicological studies and the combination of two or more assays detecting different genotoxicity endpoints in the same animals. In this study, we used 1,2-dimethylhydrazine as a model chemical of colon carcinogen to assess gene mutation frequency and chromosomal aberration in vivo simultaneously. Specifically, a gene mutation frequency assay was combined with a multiple-organ micronucleus test (peripheral blood, bone marrow, liver, and colon) in F344 gpt delta transgenic rats. Both gpt mutant frequency and micronucleated cell frequency significantly increased in colon and liver but not in bone marrow. Interestingly, we found that the colon carcinogen induced both gene mutations and micronuclei in the targeted colon tissue. Thus, we demonstrated that the mechanism of a carcinogen could be derived from an animal experiment using a lower number of experimental animals as currently recommended. Moreover, a significant increase in mutant frequency in colon and liver was already observed on the first day after treatment completion, as well as on the third day, which is the guideline-recommended period. Thus, this endpoint is compatible with other genotoxicity assays. We confirmed that performing the micronucleus assay in combination with a gene mutation assay in F344 gpt delta transgenic rats is useful to evaluate different genotoxic endpoints simultaneously in the same animals, which reduces the number of experimental animals.
化学品毒性的人体风险评估通常包括用于预测致癌性的遗传毒性试验。基因突变频率和染色体畸变是标准化体外和体内试验中的两个主要遗传毒性终点。风险评估中的证据权重方法更侧重于体内试验结果;然而,动物福利考虑旨在减少、替代和优化(3R原则)动物实验,包括减少实验动物数量。减少遗传毒性试验中实验动物数量的建议包括将遗传毒性终点纳入其他毒理学研究,以及在同一动物中组合两种或更多检测不同遗传毒性终点的试验。在本研究中,我们使用1,2 - 二甲基肼作为结肠癌致癌物的模型化学品,同时评估体内的基因突变频率和染色体畸变。具体而言,在F344 gpt delta转基因大鼠中,将基因突变频率试验与多器官微核试验(外周血、骨髓、肝脏和结肠)相结合。结肠和肝脏中的gpt突变频率和微核细胞频率均显著增加,但骨髓中未增加。有趣的是,我们发现结肠癌致癌物在目标结肠组织中既诱导了基因突变又诱导了微核形成。因此,我们证明了致癌物的作用机制可以通过使用目前推荐的较少数量的实验动物进行动物实验得出。此外,在治疗完成后的第一天以及第三天(指南推荐的时间段),结肠和肝脏中的突变频率就已经显著增加。因此,该终点与其他遗传毒性试验兼容。我们证实,在F344 gpt delta转基因大鼠中同时进行微核试验和基因突变试验,有助于在同一动物中同时评估不同的遗传毒性终点,从而减少实验动物数量。